Ftse Mib
38.567,27
0,38%
DAX
22.476,62
0,95%
S&P 500
6.013,13
0,00%
NASDAQ
19.524,01
0,00%
Bitcoin
96.041,61
-0,24%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Atara Biotherapeutics Inc (ATRA) Atara Biotherapeutics Inc (ATRA) Notizie

ATRA

Atara Biotherapeutics (ATRA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATRA
DataOraFonteTitoloSimboloCompagnia
07/02/202522:01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
07/02/202500:34Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ATRAAtara Biotherapeutics Inc
29/01/202522:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
27/01/202522:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATRAAtara Biotherapeutics Inc
21/01/202513:30Business WireAtara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219NASDAQ:ATRAAtara Biotherapeutics Inc
17/01/202522:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATRAAtara Biotherapeutics Inc
16/01/202514:30Business WireAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)NASDAQ:ATRAAtara Biotherapeutics Inc
27/11/202422:01Business WireAtara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
18/11/202423:58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
13/11/202422:01Business WireAtara Biotherapeutics to Participate at the Stifel 2024 Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
12/11/202422:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATRAAtara Biotherapeutics Inc
12/11/202422:01Business WireAtara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
05/11/202422:01Business WireAtara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024NASDAQ:ATRAAtara Biotherapeutics Inc
06/09/202400:42Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
05/09/202422:07Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ATRAAtara Biotherapeutics Inc
04/09/202422:42Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATRAAtara Biotherapeutics Inc
04/09/202422:01Business WireAtara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
03/09/202422:16Business WireAtara Biotherapeutics Announces $36 Million Registered Direct OfferingNASDAQ:ATRAAtara Biotherapeutics Inc
12/08/202423:00Business WireAtara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership UpdateNASDAQ:ATRAAtara Biotherapeutics Inc
07/08/202422:01Business WireAtara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
17/07/202415:00Business WireAtara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative DiseaseNASDAQ:ATRAAtara Biotherapeutics Inc
04/07/202401:57Business WireAtara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy ForumNASDAQ:ATRAAtara Biotherapeutics Inc
21/06/202422:01Business WireAtara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare DiseasesNASDAQ:ATRAAtara Biotherapeutics Inc
17/06/202414:00Business WireAtara Biotherapeutics Announces 1-for-25 Reverse Stock SplitNASDAQ:ATRAAtara Biotherapeutics Inc
05/06/202422:01Business WireAtara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
29/05/202422:01Business WireAtara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
23/05/202400:18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:ATRAAtara Biotherapeutics Inc
20/05/202415:25Business WireAtara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDANASDAQ:ATRAAtara Biotherapeutics Inc
10/05/202422:30Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202422:01Business WireAtara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATRA

La tua Cronologia

BIT
SPM
Saipem
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
LDO
Leonardo
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
BPE
Bper Banca
BIT
PRY
Prysmian
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
TIT
Telecom Italia
BIT
NEXI
Nexi S.p.A
BIT
CPR
Davide Campari
BIT
PST
Poste Italiane S.p.a
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci